Fractyl Health (GUTS) FCF Margin (2023 - 2024)
Fractyl Health's (GUTS) quarterly FCF Margin came in at 575566.67% in Q4 2024, down 42315238.0% YoY from N/an in Q1 2024, and down 341.48% on a QoQ basis from 130371.43% in Q3 2024.
Fractyl Health (GUTS) FCF Margin (2023 - 2024) Analysis & Trends
Fractyl Health (GUTS) has 2 years of FCF Margin data on file, last reported at 575566.67% in Q4 2024.
- Quarterly FCF Margin fell 42315238.0% year-over-year to 575566.67% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 72350.54% (down 3658887.0% YoY) and the FY2024 annual result came in at 72350.54%, down 3658887.0% from the prior year.
- FCF Margin eased to 575566.67% in Q4 2024, from 130371.43% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 16265.28% in Q2 2023 to a low of 575566.67% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 70.82% |
| 10 | Fractyl Health | 124.71 Mn | 124.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -575,566.67% |
| Sep 30, 2024 | -130,371.43% |
| Jun 30, 2024 | -46,595.35% |
| Mar 31, 2024 | -35,548.48% |
| Dec 31, 2023 | -152,414.29% |
| Sep 30, 2023 | -30,455.56% |
| Jun 30, 2023 | -16,265.28% |
| Mar 31, 2023 | -191,400.00% |